Birmingham Alabama UNITED STATES
Dr. Erik Schwiebert made the transition 11 years ago from Scientist to CEO after resigning his tenured faculty position after 11 years at the University of Alabama at Birmingham. He is the Founder and Director and remains CEO and CSO of DiscoveryBioMed, Inc. Dr. Schwiebert’s vision of integrating human cell platforms of biological and disease relevance into the Drug Discovery Critical Path is ingrained in the fabric of DBM. It derives from the focus in his academic laboratory at UAB and in his training before that of preferring to compare the physiology and pathophysiology of ion channels, receptors, and receptor channels in normal versus diseased human cells. Erik’s Ph.D. training at Dartmouth and postdoctoral training at Johns Hopkins was focused on characterizing chloride channels and sodium channels in CF versus normal lung cells and in PKD versus normal kidney cells as well as their regulation or dysregulation in the diseased state.